ReviewBest practice & research. Clinical rheumatology2009
The search for lupus biomarkers.
Review in Best practice & research. Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Genomic Landscape of Systemic Lupus Erythematosus and Lupus Nephritis Globally and the Gaps in Africa.International journal of molecular sciences · 2026Review
- Autoantibodies as Precision Tools in Connective Tissue Diseases: From Epiphenomenon to Endophenotype.Antibodies (Basel, Switzerland) · 2026Review
- Genetic variants associated with systemic inflammatory disease associate with temporomandibular symptoms with or without periodontitis.PloS one · 2026Article
- Taming renal inflammation: signaling pathways and therapeutic advances in lupus nephritis.BMC nephrology · 2025Review
- Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment.Molecules (Basel, Switzerland) · 2024Review
- Tracking of Systemic Lupus Erythematosus (SLE) Longitudinally Using Biosensor and Patient-Reported Data: A Report on the Fully Decentralized Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals-The OASIS Study.Biotech (Basel (Switzerland)) · 2023Article
- Immunoprofiling of cytokines, chemokines, and growth factors in female patients with systemic lupus erythematosus- a pilot study.BMC immunology · 2023Article
- Autoantibodies against Complement Classical Pathway Components C1q, C1r, C1s and C1-Inh in Patients with Lupus Nephritis.International journal of molecular sciences · 2022Article
- Mayan alleles of the HLA-DRB1 major histocompatibility complex might contribute to the genetic susceptibility to systemic lupus erythematosus in Mexican patients from Tapachula, Chiapas.Clinical rheumatology · 2021Article
- Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus.International journal of molecular sciences · 2021Review
- Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus.Biomolecules · 2021Review
- Long Non-Coding RNAs as New Biomarkers in Lupus Nephritis: A Connection Between Present and Future.Cureus · 2020Review
- Predictive value of the neutrophil-to-lymphocyte ratio and hemoglobin insystemic lupus erythematosus.Experimental and therapeutic medicine · 2018Article
- Platelet distribution width as a novel indicator of disease activity in systemic lupus erythematosus.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2018Article
- Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.Arthritis research & therapy · 2017Article
- Pathways of impending disease flare in African-American systemic lupus erythematosus patients.Journal of autoimmunity · 2017Article
- Neutrophil to Lymphocyte Ratio and Mean Platelet Volume as Inflammatory Indicators in Systemic Lupus Erythematosus Nephritis.Archives of rheumatology · 2017Article
- Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2017Article
- Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Few biomarkers for systemic lupus erythematosus (SLE) have been validated and employed for making clinical decisions. The lack of reliable, specific biomarkers for SLE hampers the proper clinical management of patients with SLE and impedes the development of new lupus therapeutics. This void has led to renewed enthusiasm for identifying biomarkers that precisely and specifically reflect the pathophysiological and clinical changes of SLE. Several laboratory markers have shown early promise as biomarkers for lupus susceptibility, diagnosis and monitoring. These include polymorphisms and copy-number variations of complement C4 and Fcgamma receptor genes (disease susceptibility), cell-bound complement C4d (diagnosis and/or disease activity), CD27(high) plasma cells (disease activity), 'interferon signature' (disease activity) and anti-C1q and anti-NMDA (disease activity and organ involvement). Although these and other promising candidate biomarkers have been identified, they still need to be validated through rigorous, large-scale multicentre studies. This article briefly reviews the historical aspects of lupus biomarkers and summarises current efforts to advance the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.